Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13425MR)

This product GTTS-WQ13425MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13425MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11111MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ14076MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ5313MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ1827MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ6258MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ5059MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ13382MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ596MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW